Table of Contents

• Recent Progress on Urinary Exosomal miRNAs in Bladder Cancer

  Mohan Dong, Kaiyuan Zhou

  Bladder cancer (Bca) is one of the most common tumors in the urinary system. Cystoscopy biopsy is a gold standard for diagnosis of Bca in the clinic. However, cystoscopy biopsy is invasive, costly and invasive process causing pain in the patients. Because the Bca cells are closely in contact with urine, and the exosomes of the Bca can pass through the base membrane and transport the microRNA (miRN...

  REVIEW | Published: 18 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 39-46   PDF(734KB)   Views：909Downloads：8

• The Application of Exosomes in the Diagnosis and Treatment of Renal Cell Carcinoma

  Xian Zhao, Jian Gong

  Renal cell carcinoma (RCC) is an epithelial tumor originating from the proximal renal tubule of the urinary system. RCC is one of the most common and deadly tumors representing clear cell renal cell carcinoma (ccRCC) (about 75%) as major subtype characterized by high incidence and poor prognosis. There are no obvious clinical symptoms in the early stage ccRCC, but are readily visible in the late s...

  REVIEW | Published: 17 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 47-53   PDF(524KB)   Views：770Downloads：9

• Research Progress on Circulating Tumor DNA in Renal Cell Carcinoma

  Xinyi Zhang, Mohan Dong, Kaiyuan Zhou

  Renal cell carcinoma (RCC) is one of the most common tumors in urinary system, and its incidence ranks 7th and 8th in male and female in the United States with a continuous upward trend in last 5 years. In China, RCC also shows a significant growth trend. Because the early symptoms are not obvious, many patients are diagnosed at an advanced stage of the disease and often have a poor prognosis. Th...

  REVIEW | Published: 16 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 54-62   PDF(618KB)   Views：898Downloads：7

• Treatment Options for Renal Cell Carcinoma: Mechanisms and Outcomes

  Benjamin Ptasienski, Jake Myers ... Yujiang Fang

  Renal Cell Carcinoma (RCC), cancer of the tubules of the kidneys, has historically been one of the most difficult cancers to treat due to its ability to remain hidden in the body for longer than other cancers and its tendency to resist traditional forms of chemotherapy and radiation therapy. However, both traditional and nontraditional treatments of RCC have seen both significant biomedical advanc...

  REVIEW | Published: 28 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 63-69   PDF(560KB)   Views：835Downloads：9

• Advances in Immunotherapy and Vaccine for Prostate Cancer

  Wei Zhou, Yikai Zhang

  Prostate cancer is one of the most common malignant tumors of the urinary system. The incidence of prostate cancer is high in the elderly male patients, which seriously threatens the life and health. In recent years, immunotherapy to activate anti-cancer host immune cells to kill tumors has become a new area of research for the treatment of prostate cancer. As an important component of immunothera...

  REVIEW | Published: 28 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 70-78   PDF(744KB)   Views：786Downloads：10

• Research Progress in Focal Treatment of Prostate Cancer

  Songtao Cheng, Shize Wang ... Jiannan Liu

  Prostate cancer is the second most common malignant tumor in men worldwide, and its incidence is increasing in China. Treatment methods of prostate cancer include surgery, radiotherapy, chemotherapy, endocrine therapy, and local therapy. Compared to all treatment options for prostate cancer, local treatment has the advantage of less trauma and fewer complications. With the wide application of PSA ...

  REVIEW | Published: 28 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 79-86   PDF(614KB)   Views：602Downloads：5